Buy Laurus Labs; target of Rs 580: Motilal Oswal
Motilal Oswal is bullish on Laurus Labs recommended buy rating on the stock with a target price of Rs 580 in its research report dated January 28, 2022.01-02-2022
01-02-2022
Laurus Labs: Diversification away from ARVs on track
The share of the Laurus antiretroviral business in total is expected to be less than 1/3rd by 2025, compared to 50 percent now as the company's other engines of growth gain traction31-01-2022
Buy Laurus Lab; target of Rs 625: ICICI Direct
ICICI Direct is bullish on Laurus Lab recommended buy rating on the stock with a target price of Rs 625 in its research report dated January 28, 2022.29-01-2022
Earnings Call for Q3FY22 of Laurus Labs
Conference Call with Laurus Labs Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript.28-01-2022
Laurus Labs Ltd - 540222 - Audio Recording Of The Q3 9M FY22 Earnings' Conference Call Hosted On January 28, 2022
Audio Recording of the Q3 9M FY22 Earnings' conference call hosted on January 28, 202228-01-2022
Laurus Labs bounces 16% from day's low on heavy volumes
The company said its Q3FY22 results were impacted by lower sales of ARV, APIs and formulations due to stocking at channel partners and it expects improvement from January-March quarter (Q4).28-01-2022
Q3FY22 Quarterly Result Announced for Laurus Labs Ltd.
Pharmaceuticals and biotechnology company Laurus Labs announced Q3FY22 results: Q3 FY22 : Total net revenue Rs 1,029 crore, decreased 20 % (YoY) EBITDA Rs 290 crore, decreased by 33 % (YoY) EBITDA margins at 28 % PAT at Rs 154 crore, decreased by 44 % (YoY) PAT margins at 15 % (YoY) EPS (Diluted) for the period at Rs 2.9 per share (not annualised) 9M FY22 : Revenue at Rs 3,511 crore, up 3 % (YoY) EBITDA Rs 1,038 crore, decreased by 5 % (YoY) EBITDA margins at 30 % PAT at Rs 597 crore, decreased by 13 % (YoY) PAT margins at 17 % EPS (Diluted) (face value of Rs 2/-) for the period at Rs 11.1 per share (not annualised) Commenting on the highlights, Founder and Chief Executive Officer Dr. Satyanarayana Chava stated “Our 9MFY22 results reflects operational resilience overall with better mix and sustained profitability despite of lower revenue from ARV APIs and formulations. Our Q3 results impacted by lower sales of ARV APIs and formulations due to stocking at channel partners and we expect improvement from Q4. However, Strong momentum in our CDMO business continued this quarter with over 60% growth and also seen healthy rebound in API business (ex-ARV) with activity levels picking up. We continue to sharpen our execution as we focus on positioning our businesses for sustainable long term growth” Commenting on the results announcement, V V Ravi Kumar, ED & Chief Financial Officer said; “Laurus Labs reported 9MFY22, our Revenues have grown 3% to Rs 3,511 crs, driven by Strong CDMO business, steady FDF and likely rebound in Other APIs. EBITDA came at Rs 1,038 crs with EBITDA margins at 30% as better mix compensated for negative operating leverage. Q3 Revenues of Rs 1,029 crs, fell 20% YoY, impacted by continued stocking concern in ARV business. Despite a tough environment we have demonstrated healthy Gross Margins expansion due to better mix. EBITDA has declined by 33% to Rs 290 crs while our EBITDA margins were largely consistent at 28%.” Result PDF27-01-2022
Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release on Q3 Financials FY 202227-01-2022
Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor PPT for Q3 Financials FY 2227-01-2022